(redirected from Hereditary angioedema)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for angioedema

recurrent large circumscribed areas of subcutaneous edema

References in periodicals archive ?
Safety and Efficacy of Nanofiltered C1 Esterase Inhibitor (Human) (C1 INH-nf) for the Treatment of Laryngeal Attacks in Subjects with Hereditary Angioedema (HAE)
The United States Hereditary Angioedema Association (HAEA) is a not-for profit organization that represents approximately 2,300 HAE families.
ViroPharma commercializes Cinryze (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).
Cinryze is a C1 inhibitor replacement therapy that treats the underlying cause of hereditary angioedema (HAE) - a deficiency of the C1 inhibitor plasma protein that mediates swelling.
HAE is an especially challenging disease for patients to manage, said Anthony Castaldo, President of the Hereditary Angioedema Association (US HAEA), a non-profit patient services and research organization with a membership of over 5,000 HAE patients in the United States.
Sponsoring of an HAE symposium at the Second Latin-American Congress on Hereditary Angioedema in Veracruz, Mexico
ViroPharma Incorporated (NASDAQ: VPHM), today announced its support of the second annual international Hereditary Angioedema Day.
DX-2930 may be a viable prophylactic treatment option for hereditary angioedema and other plasma kallikrein-mediated (PKM) diseases.
The drug, dubbed Cinryze, is the only drug in Europe with the indication for the prevention of hereditary angioedema and was introduced on the US market several years ago, news agency Europa Press quoted the director of the Spanish unit of ViroPharma, Gilbert Credi, as saying today.
SeeNews) - Nov 7, 2012 - Dutch biotechnology firm Pharming Group NV (AMS:PHARM) and US Santarus Inc (NASDAQ:SNTS) unveiled today promising top-line Phase III data for Ruconest (recombinant human C1 esterase inhibitor) in acute hereditary angioedema.
Recent laboratory research into the pathophysiology of hereditary angioedema (HAE) has identified bradykinin as a crucial vasoactive compound in the pathophysiology of attacks (3).
Hereditary angioedema (HAE) is a relatively rare, potentially life-threatening condition caused by a genetic (autosomal dominant) deficiency of C 1 esterase inhibitor (C1-INH), a human plasma protein that regulates the contact (bradykinin-forming), complement, and fibrinolytic systems.
Angioedema in a patient with positive family history and low C4 is characteristic of hereditary angioedema (HAE).
SAN DIEGO -- Patients with hereditary angioedema wait 15 years on average between the onset of symptoms and diagnosis, according to a poster that was presented at the annual meeting of the American Association for Allergy, Asthma, and Immunology.
Full browser ?